Equities analysts expect NxStage Medical, Inc. (NASDAQ:NXTM) to report sales of $96.70 million for the current quarter, Zacks reports. Three analysts have made estimates for NxStage Medical’s earnings, with the highest sales estimate coming in at $97.10 million and the lowest estimate coming in at $96.10 million. NxStage Medical posted sales of $92.21 million in the same quarter last year, which suggests a positive year over year growth rate of 4.9%. The company is expected to issue its next earnings report before the market opens on Wednesday, August 9th.
On average, analysts expect that NxStage Medical will report full-year sales of $96.70 million for the current year, with estimates ranging from $400.50 million to $402.90 million. For the next financial year, analysts anticipate that the business will post sales of $445.51 million per share, with estimates ranging from $436.45 million to $461.10 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Tuesday, May 9th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. NxStage Medical had a negative return on equity of 2.31% and a negative net margin of 1.25%. The company had revenue of $96.83 million during the quarter, compared to the consensus estimate of $95.31 million. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year.
Several research firms have weighed in on NXTM. Jefferies Group LLC cut their price target on NxStage Medical from $38.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. BidaskClub cut NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday. Canaccord Genuity restated a “buy” rating and set a $32.00 price target on shares of NxStage Medical in a report on Monday, May 8th. Craig Hallum assumed coverage on NxStage Medical in a report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 target price for the company. Finally, BTIG Research reiterated a “buy” rating and issued a $27.00 target price on shares of NxStage Medical in a report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. NxStage Medical has an average rating of “Hold” and a consensus price target of $30.50.
NxStage Medical (NASDAQ:NXTM) traded down 1.06% on Friday, hitting $23.30. The stock had a trading volume of 373,287 shares. NxStage Medical has a 1-year low of $20.45 and a 1-year high of $30.80. The stock’s market capitalization is $1.53 billion. The company has a 50-day moving average price of $24.09 and a 200-day moving average price of $25.85.
In other news, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total value of $25,190.00. Following the completion of the transaction, the president now owns 75,903 shares in the company, valued at approximately $1,911,996.57. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $21.36, for a total value of $91,848.00. Following the completion of the transaction, the senior vice president now owns 29,637 shares of the company’s stock, valued at approximately $633,046.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,150 shares of company stock valued at $538,441. Company insiders own 4.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in NXTM. SG Americas Securities LLC acquired a new stake in shares of NxStage Medical during the first quarter worth about $140,000. Ameritas Investment Partners Inc. acquired a new stake in shares of NxStage Medical during the first quarter worth about $148,000. Menta Capital LLC acquired a new stake in shares of NxStage Medical during the first quarter worth about $212,000. Jane Street Group LLC acquired a new stake in shares of NxStage Medical during the first quarter worth about $213,000. Finally, PEAK6 Investments L.P. acquired a new stake in shares of NxStage Medical during the first quarter worth about $214,000. Hedge funds and other institutional investors own 95.41% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/12/nxstage-medical-inc-nxtm-expected-to-post-quarterly-sales-of-96-70-million-updated.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.